Healthy volunteers help compare two forms of experimental drug amlitelimab

NCT ID NCT05796479

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested two different versions of the experimental drug amlitelimab in 32 healthy adults. The goal was to see how the body absorbs and processes each version and to check for any safety issues. Participants received a single injection and were monitored for about 17 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

amlitelimab

What could go wrong

This is an early-phase study in healthy volunteers, not patients, so it cannot show whether the drug works for any disease. The main goal is just to compare two versions of the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Pharmacology of Miami-Site Number: 8400001

    Hialeah, Florida, 33014, United States